$APRE
Aprea Therapeutics, Inc.

2021 Form 10-K Financial Statement

#000155837022003671 Filed on March 15, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.55M $4.900M $14.93M
YoY Change -9.24% 24.37% 73.81%
% of Gross Profit
Research & Development $23.90M $9.330M $37.88M
YoY Change -36.92% 16.04% 80.8%
% of Gross Profit
Depreciation & Amortization $12.83K $20.00K $28.83K
YoY Change -55.51% 159.16%
% of Gross Profit
Operating Expenses $37.45M $14.22M $52.81M
YoY Change -29.09% 18.7% 78.75%
Operating Profit -$37.45M
YoY Change
Interest Expense $1.648K -$1.170M $222.7K
YoY Change -99.26% 7.34% 42.41%
% of Operating Profit
Other Income/Expense, Net $319.1K -$667.6K
YoY Change -147.79% -144.97%
Pretax Income -$37.13M -$15.39M -$53.48M
YoY Change -30.58% 17.75% 90.59%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$37.13M -$15.39M -$53.48M
YoY Change -30.58% 17.75% 90.59%
Net Earnings / Revenue
Basic Earnings Per Share -$1.74 -$2.53
Diluted Earnings Per Share -$1.74 -$726.3K -$2.53
COMMON SHARES
Basic Shares Outstanding 21.29M 21.13M
Diluted Shares Outstanding 21.29M 21.13M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.08M $89.00M $89.00M
YoY Change -40.36% -31.59% -31.59%
Cash & Equivalents $53.08M $89.02M $89.00M
Short-Term Investments
Other Short-Term Assets $3.508M $3.400M $3.400M
YoY Change 3.19% 13.33% 13.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $56.58M $92.42M $92.40M
YoY Change -38.76% -30.51% -30.53%
LONG-TERM ASSETS
Property, Plant & Equipment $209.7K $38.52K $400.0K
YoY Change -47.58% -93.58% -33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $29.37K $29.38K $0.00
YoY Change
Total Long-Term Assets $239.1K $388.5K $400.0K
YoY Change -40.24% -35.25% -33.33%
TOTAL ASSETS
Total Short-Term Assets $56.58M $92.42M $92.40M
Total Long-Term Assets $239.1K $388.5K $400.0K
Total Assets $56.82M $92.81M $92.80M
YoY Change -38.77% -30.54% -30.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.773M $4.504M $4.500M
YoY Change -60.6% 104.71% 104.55%
Accrued Expenses $5.543M $10.80M $10.80M
YoY Change -48.67% 56.52% 56.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.317M $15.33M $15.30M
YoY Change -52.18% 68.47% 68.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $100.0K $100.0K
YoY Change -100.0% -66.67% -66.67%
Total Long-Term Liabilities $0.00 $100.0K $100.0K
YoY Change -100.0% -66.67% -66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.317M $15.33M $15.30M
Total Long-Term Liabilities $0.00 $100.0K $100.0K
Total Liabilities $7.317M $15.41M $15.40M
YoY Change -52.49% 63.94% 63.83%
SHAREHOLDERS EQUITY
Retained Earnings -$144.0M
YoY Change
Common Stock $21.19K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.51M $77.40M $77.40M
YoY Change
Total Liabilities & Shareholders Equity $56.82M $92.81M $92.80M
YoY Change -38.77% -30.54% -30.54%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$37.13M -$15.39M -$53.48M
YoY Change -30.58% 17.75% 90.59%
Depreciation, Depletion And Amortization $12.83K $20.00K $28.83K
YoY Change -55.51% 159.16%
Cash From Operating Activities -$37.69M -$13.20M -$41.80M
YoY Change -9.85% -10.45% 56.51%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$20.00K $25.71K
YoY Change -100.0% 100.0% -16.8%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$20.00K -$25.71K
YoY Change -100.0% 100.0% -16.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.500M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.747M 0.000 150.9K
YoY Change 1057.35% -100.0% -99.84%
NET CHANGE
Cash From Operating Activities -37.69M -13.20M -41.80M
Cash From Investing Activities 0.000 -20.00K -25.71K
Cash From Financing Activities 1.747M 0.000 150.9K
Net Change In Cash -35.94M -13.22M -41.68M
YoY Change -13.77% -117.29% -163.3%
FREE CASH FLOW
Cash From Operating Activities -$37.69M -$13.20M -$41.80M
Capital Expenditures $0.00 -$20.00K $25.71K
Free Cash Flow -$37.69M -$13.18M -$41.83M
YoY Change -9.9% -10.52% 56.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.53
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001781983
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39069
CY2021 dei Entity Registrant Name
EntityRegistrantName
Aprea Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-2246769
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
535 Boylston Street
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.67
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21286547
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21133651
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6002486
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21859413
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21186827
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei City Area Code
CityAreaCode
617
CY2021 dei Local Phone Number
LocalPhoneNumber
463-9385
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
APRE
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
70400000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21974302
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Iselin, New Jersey
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53076052
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89017686
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3508358
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3399019
CY2021Q4 us-gaap Assets Current
AssetsCurrent
56584410
CY2020Q4 us-gaap Assets Current
AssetsCurrent
92416705
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23870
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38515
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
185811
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
320616
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29372
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29383
CY2021Q4 us-gaap Assets
Assets
56823463
CY2020Q4 us-gaap Assets
Assets
92805219
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1773032
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4503619
CY2021Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
5352996
CY2020Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
10571237
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
190471
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
256309
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7316499
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15331165
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
78847
CY2021Q4 us-gaap Liabilities
Liabilities
7316499
CY2020Q4 us-gaap Liabilities
Liabilities
15410012
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21859413
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21186827
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
21859
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
21187
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
240978439
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
231418356
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10358956
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10037261
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-181134378
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-144007075
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
49506964
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
77395207
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56823463
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92805219
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23895875
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37879325
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20950672
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13550478
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14931887
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8593626
CY2021 us-gaap Operating Expenses
OperatingExpenses
37446353
CY2020 us-gaap Operating Expenses
OperatingExpenses
52811212
CY2019 us-gaap Operating Expenses
OperatingExpenses
29544298
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1648
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
222652
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
156351
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
317402
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-890252
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1328140
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
319050
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-667600
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1484491
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-37127303
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-53478812
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-28059807
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-321695
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1496517
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2772453
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37448998
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51982295
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30832260
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.53
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.67
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21286547
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21133651
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6002486
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-51436102
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70997
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1345722
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2772453
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
118188993
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-28059807
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
124243530
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
150949
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4983023
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1496517
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-53478812
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
77395207
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
208367
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1538645
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7813743
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-321695
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-37127303
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
49506964
CY2021 us-gaap Profit Loss
ProfitLoss
-37127303
CY2020 us-gaap Profit Loss
ProfitLoss
-53478812
CY2019 us-gaap Profit Loss
ProfitLoss
-28059807
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12829
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28834
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11126
CY2021 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
7813743
CY2020 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
4983023
CY2019 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
1345722
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
258848
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
200776
CY2019 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
159128
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
317402
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-890252
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1328140
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
109338
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
472402
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2633732
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2730587
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2326767
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
437515
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5218241
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3928684
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3513782
CY2021 apre Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-268728
CY2020 apre Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-209794
CY2019 apre Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-154301
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37686179
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41802672
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26708707
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25709
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30901
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25709
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30901
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
208367
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
150949
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
70997
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
86906179
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1538645
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
5598362
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1747012
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
150949
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
92575538
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-35939167
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-41677432
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
65835930
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2467
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
606249
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1422992
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89017686
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130088869
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65675931
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53076052
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89017686
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130088869
CY2021 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
124043
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Cash
Cash
53100000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>— The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of credit risk</b>—Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p>
CY2021 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
114280
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23870
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38515
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12829
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28834
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11126
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4986334
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3771459
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3499934
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
140877
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
152795
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
117007
CY2021Q4 apre Lessee Operating Lease Number Of Operating Leases
LesseeOperatingLeaseNumberOfOperatingLeases
2
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
236364
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
226275
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
161856
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
255078
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
251636
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
174846
CY2021 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
124043
CY2019 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
355330
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
193980
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
193980
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3509
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
190471
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
247123
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
224424
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1418309
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1515312
CY2021Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
3504375
CY2020Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
8158302
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
183189
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
673199
CY2021Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
5352996
CY2020Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
10571237
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-37127303
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-53478812
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-28059807
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.002
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.017
CY2019 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.037
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.182
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.225
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.251
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.027
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38773870
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32183004
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3341338
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1358554
CY2021Q4 apre Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
47677
CY2020Q4 apre Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
70192
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42162885
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33611750
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42115543
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33541533
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
47342
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
70217
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
818
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1130
CY2021Q4 apre Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
46524
CY2020Q4 apre Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
69087
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
47342
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
70217
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8600000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13900000
CY2021Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
800000
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
0
CY2021Q4 apre Stock Shares Authorized
StockSharesAuthorized
440000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021 apre Common Stock Number Of Voting Rights Per Share
CommonStockNumberOfVotingRightsPerShare
1
CY2020Q4 apre Universal Shelf Registration Maximum Amount To Be Issued
UniversalShelfRegistrationMaximumAmountToBeIssued
350000000.0
CY2020Q4 apre At Market Offering Program Maximum Amount To Be Issued
AtMarketOfferingProgramMaximumAmountToBeIssued
50000000.0
CY2020Q4 apre At Market Offering Commission Payable As Percentage Of Gross Proceeds From Sale Of Common Stock
AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock
0.03
CY2021 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
366773
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1500000
CY2020 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0
CY2021 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0

Files In Submission

Name View Source Status
0001558370-22-003671-index-headers.html Edgar Link pending
0001558370-22-003671-index.html Edgar Link pending
0001558370-22-003671.txt Edgar Link pending
0001558370-22-003671-xbrl.zip Edgar Link pending
apre-20211231.xsd Edgar Link pending
apre-20211231x10k.htm Edgar Link pending
apre-20211231x10k001.jpg Edgar Link pending
apre-20211231x10k002.jpg Edgar Link pending
apre-20211231x10k003.jpg Edgar Link pending
apre-20211231x10k_htm.xml Edgar Link completed
apre-20211231xex21d1.htm Edgar Link pending
apre-20211231xex23d1.htm Edgar Link pending
apre-20211231xex31d1.htm Edgar Link pending
apre-20211231xex31d2.htm Edgar Link pending
apre-20211231xex32d1.htm Edgar Link pending
apre-20211231xex32d2.htm Edgar Link pending
apre-20211231_cal.xml Edgar Link unprocessable
apre-20211231_def.xml Edgar Link unprocessable
apre-20211231_lab.xml Edgar Link unprocessable
apre-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending